Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial
Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Robin Foà(Sapienza University of Rome), Giuseppe Gritti(Ospedale Papa Giovanni XXIII), Daniele Vincenti(University of Milan), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Nicola Cascavilla, Francesca Romana Mauro(Sapienza University of Rome), Fortunato Morabito(Azienda Ospedaliera di Cosenza), Gianluigi Reda(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Luca Laurenti(Sapienza University of Rome), Annalisa Chiarenza(University of Catania), Francesco Zaja, Alfonso Piciocchi(Fondazione Gimema Onlus), Antonino Neri(University of Milan), Anna Guarini(Sapienza University of Rome), A. M. Liberati(University of Perugia), Sonia Fabris(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Mariarita Sciumé(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Antonio Cuneo(Arcispedale Sant'Anna), Sergio Storti(Università Cattolica del Sacro Cuore), Lorella Orsucci(Azienda Ospedaliero Universitaria San Giovanni Battista), Emanuele Angelucci(Ospedale Policlinico San Martino), Marco Vignetti(Fondazione Gimema Onlus), Roberto Marasca(University of Modena and Reggio Emilia), Marco Gobbi(Mario Negri Institute for Pharmacological Research), Diana Giannarelli(Agostino Gemelli University Polyclinic)
Cited by 58
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
|Leukemia|2009|877
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644